文献速递白血病造血干细胞移植与细胞治疗

青年及青少年Ph阴性ALL首次缓解后:儿童型化疗生存优于清髓性异基因移植

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
PubMed 文献 · Leukemia · 2021-03-30

本研究比较CALGB 10403方案中接受儿童型化疗的青少年和青年(AYA)Ph阴性急性淋巴细胞白血病(ALL)首次完全缓解(CR1)患者与接受清髓性异基因造血干细胞移植(HCT)患者的结局。结果显示化疗组3年总生存(OS)优于移植组(77% vs 53%,P<0.001),多因素分析中移植与更差OS、无病生存(DFS)及更高非复发死亡(NRM)相关,但化疗组5年复发率更高(34% vs 23%,P=0.011)。肥胖与更差生存独立相关。

要点

  • AYA Ph阴性ALL CR1患者,儿童型化疗较清髓性异基因HCT有更优OS、DFS和更低NRM。
  • 化疗组5年复发率高于移植组(34% vs 23%,P=0.011)。
  • 肥胖是OS、DFS、复发和NRM的不良独立因素。

核心结论

  • 对于AYA Ph阴性ALL CR1患者,儿童型化疗作为缓解后治疗在OS、DFS和NRM方面优于清髓性异基因HCT。

研究设计与样本

  • 比较CALGB 10403研究中接受儿童型化疗的患者与在CR1接受清髓性异基因HCT的队列,分析OS、DFS、复发和NRM。

主要发现

  • 单因素分析显示化疗组3年OS优于移植组(77% vs 53%,P<0.001)。
  • 多因素分析显示异基因HCT较化疗OS更差(HR 2.00,95%CI 1.5-2.66,P<0.001),DFS更差(HR 1.62,95%CI 1.25-2.12,P<0.001),NRM更高(HR 5.41,95%CI 3.23-9.06,P<0.001)。
  • 化疗组5年复发率高于异基因HCT组(34% vs 23%,P=0.011)。
  • 肥胖独立关联更差OS(HR 2.17,95%CI 1.63-2.89,P<0.001)、更差DFS(HR 1.97,95%CI 1.51-2.57,P<0.001)、更高复发(HR 1.84,95%CI 1.31-2.59,P<0.001)和更高NRM(HR 2.10,95%CI 1.37-3.23,P<0.001)。

临床怎么用

  • 在AYA Ph阴性ALL CR1患者中,选择缓解后治疗时儿童型化疗可能优于清髓性异基因HCT。
  • 需权衡化疗较高的复发风险与移植较高的NRM。
  • 肥胖患者预后更差,需关注体重管理及强化监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. In univariate analysis, OS was superior with chemotherapy compared to MA allogeneic HCT (3-year OS 77% vs. 53%, P < 0.001). In multivariate analysis, allogeneic HCT showed inferior OS (HR 2.00, 95% CI 1.5-2.66, P < 0.001), inferior DFS (HR 1.62, 95% CI 1.25-2.12, P < 0.001), and increased NRM (HR 5.41, 95% CI 3.23-9.06, P < 0.001) compared to chemotherapy. A higher 5-year relapse incidence was seen with chemotherapy compared to allogeneic HCT (34% vs. 23%, P = 0.011). Obesity was independently associated with inferior OS (HR 2.17, 95% CI 1.63-2.89, P < 0.001), inferior DFS (HR 1.97, 95% CI 1.51-2.57, P < 0.001), increased relapse (1.84, 95% CI 1.31-2.59, P < 0.001), and increased NRM (HR 2.10, 95% CI 1.37-3.23, P < 0.001). For AYA ALL patients in CR1, post-remission therapy with pediatric-style chemotherapy is superior to MA allogeneic HCT for OS, DFS, and NRM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wieduwilt MJ, Stock W, Advani A, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021. PMID: 33785862. doi:10.1038/s41375-021-01213-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。